Markets
BDX

BD Wins FDA Clearance For EnCor EnCompass Breast Biopsy System

January 15, 2026 — 07:32 am EST

Written by RTTNews.com for RTTNews->

(RTTNews) - Becton, Dickinson and Company (BDX) on Thursday said the U.S. Food and Drug Administration has cleared its EnCor EnCompass Breast Biopsy and Tissue Removal System.

The EnCor EnCompass system is designed to allow clinicians to perform breast biopsy procedures across multiple imaging platforms using a single integrated system.

The device is expected to launch in early 2026.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

BDX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.